Signal Transducer and Activator of Transcription 5 (STAT5) protein, a component of the STAT family of signaling proteins, is considered to be an attractive therapeutic target because of its involvement in the progression of acute myeloid leukemia. In an effort to discover potent molecules able to inhibit the phosphorylation-activation of STAT5, twenty-two compounds were synthesized and evaluated on the basis of our knowledge of the activity of 2-(3′,4′,5′-trimethoxybenzoyl)-3-iodoacetamido-6-methoxybenzo [b]furan derivative 1 as a potent STAT5 inhibitor. Most of these molecules, structurally related to compound 1, were characterized by the presence of a common 3′,4′,5′-trimethoxybenzoyl moiety at the 2-position of different benzoheterocycles such as benzo 
Introduction
The ultimate goal of research in cancer therapy is to develop treatments that specifically target the cancer cell while leaving normal cells intact. The introduction of the BCR-ABL tyrosine kinase inhibitor imatinib in chronic myelogenous leukemia (CML) therapy has been a major advance in leukemia treatment [1] [2] [3] . However, clinical drug resistance often can develop through the acquisition of BCR-ABL gene mutations, which make this oncoprotein refractory to inhibition by imatinib or other tyrosine kinase inhibitors, such as nilotinib and dasatinib. In addition, BCR-ABL independent mechanisms of resistance were also described [4] [5] [6] . Therefore, the hunt for better effective agents is ongoing.
The identification of novel compounds modulating the expression/activity of molecular targets downstream to BCR-ABL could be a new approach in the treatment of CML resistant to BCR-ABL targeted molecules. In fact, the mechanism through which BCR-ABL contributes to malignant transformation is dependent from the ability of this oncoprotein to activate a variety of signaling pathways and downstream targets such as STAT5, RAS, phosphatidylinositol-3′-kinase (PI3K), and others [7] [8] [9] [10] . Many studies have shown that constitutive activation of the gene Signal Transducers and Activators of Transcription 5 (STAT5) plays an important role in the pathogenesis of CML induced by BCR-ABL [11] [12] [13] [14] , as well as in acute myeloid leukemias (AML) [15] [16] [17] and in polycythemia rubra vera [18, 19] . STAT5 is the component of a family of seven proteins (STAT1-6) critical for the pathogenesis of many tumors [20] [21] [22] , but these proteins are largely dispensable in normal adult cells [23] , suggesting that they could be targets with a high therapeutic index [24] [25] [26] . STAT proteins transduce signals from the cell surface to the nucleus, where they regulate the expression of genes that control proliferation, survival, selfrenewal, and other critical cellular functions [27] . Under normal physiological conditions, the activation of STATs is tightly regulated. In cancer, by contrast, STAT proteins, particularly STAT3 and STAT5 [28] , become activated constitutively, thereby driving the malignant phenotype of cancer cells [29] [30] [31] [32] .
In order to be functional, STAT5 protein must first be activated. This activation is carried out by kinases associated with transmembrane receptors at the cell surface. First, ligands (cytokines, growth factors) binding to these transmembrane receptors on the outside of the cell activate Janus kinase 2 (JAK2), which in turn adds a phosphate group to a specific tyrosine residue on the receptor. STAT5 then binds to these phosphorylated-tyrosines using their SH2 domain. The bound STAT5 is then phosphorylated by JAK2, and the phosphorylated STAT5 (pSTAT5) finally goes on to form either homodimers, STAT5-STAT5, or heterodimers, STAT5-STATX with other STAT proteins [33, 34] . The STAT5 dimer then translocates to the nucleus, where STAT5 binds to a consensus DNA sequence and promotes expression of specific STAT5 target genes (e.g., Bcl-xl, c-Myc, pim-1, p21, MCL-1, Osm and JAB).
Differently from normal cells, in which STAT5 is activated by JAK2, in CML the product of the fusion protein BCR-ABL directly activates the STAT5 protein. Activated STAT5 seems to plays a crucial role in growth and survival of CML cells, suggesting that drugs able to inhibit STAT5 activation could be useful for the treatment of this type of leukemia, especially for CML resistant to BCR-ABL targeted molecules [35] . However, despite many years of intensive research devoted to the discovery of small molecules targeting STAT5, none of the direct inhibitors of STAT5 [36] [37] [38] [39] [40] [41] [42] have been approved for clinical use in oncology.
Previously we synthesized a new series of 2-(3′,4′,5′-trimethoxybenzoyl)-3-aminobenzo [b] furan compounds that showed cytotoxic activity in BCR-ABL expressing cells [43] . Among them, we identified the 2-(3′,4′,5′-trimethoxybenzoyl)-3-iodoacetamido-6-methoxybenzo [b] furan derivative 1 (TR120) as a potent inductor of apoptosis in the BCR-ABL-positive K562 and KCL-22 cell lines and in their imatinib resistant counterpart K562-R and KCL22-R cells in vitro (Chart 1). Compound 1 induced a marked decrease in the pSTAT5 level in these cell lines, along with a block of cells in G1, a decrease in cyclin D expression and an increase in the percentage of apoptotic cells [44] . Preliminary structureactivity relationship (SAR) analysis indicated that the iodoacetamido function at the C-3 position of the benzo[b]furan ring system was essential for STAT5 inhibitory activity, while the corresponding bromoacetylamino and chloroacetylamino analogs were inactive. The activity of compound 1 as a STAT5 inhibitor caused us to undertake a further SAR study, by the design and synthesis of different series of derivatives. All the synthesized compounds were characterized by the presence of an electrophilic iodoacetamido function that can potentially react with essential thiol groups in the STAT5 functional domains and thus alter their function.
By the preparation of the corresponding isomeric analogs 2 and 3, which retain the iodoacetylamino moiety at the C-3 position of 2-(3′,4″,5-trimethoxybenzoyl)benzo[b]furan skeleton, we turned our attention to the position of the methoxy group, by moving it to either the C-5 or C-7 position of the benzo[b]furan system, respectively. Compound 4 was unsubstituted on the benzene portion of the benzo[b]furan ring. Since the iodoacetylamino had proved to be favorable for activity, through the synthesis of compounds 5-12 we investigated the effect on biological activity of moving the iodoacetylamino function from the 3 to the 4, 5, 6 or 7-position of the 2-(3′,4′,5′-trimethoxybenzoyl)benzo[b]furan nucleus. Finally, we prepared a set of 2-(3′,4′,5′-trimethoxybenzoyl) benzoheterocyclic derivatives structurally related to 1, obtained by replacing the original benzo[b]furan nucleus with various bio-isosteric benzoheterocycles such as indole (13) , N-methylindole (14, 15) and benzo [b] thiophene (16) (17) (18) (19) (20) . Besides the methoxy group, another substituent examined was the weak electron-donating methyl substituent in the benzene portion of the benzo[b]heterocyclic system. Since the 3,4,5-trimethoxyphenyl group is found in many antitubulin compounds, such as colchicine, podophyllotoxin and combretastatin A-4 (CA-4) [45] , by the synthesis of compounds 21-23 we investigated the influence of the 3,4,5-trimethoxybenzoyl group at the 2-position of the 3-iodoacetylamino benzo[b]furan derivative 4 on STAT5 inhibitory activity, by the substitution of this moiety with a 3,4-dimethoxybenzoyl (21), 4-methoxybenzoyl (22) or benzoyl (23) group.
Chemistry
The synthesis of eight of the twenty-two compounds (2-4 and 16-20) was previously described by our research group [46] Table 1 shows the cytotoxic effects evaluated as IC 50 (concentration able to inhibit cell growth by 50%) and AC 50 (concentration able to induce apoptosis in 50% of the cells) of iodoacetamido derivatives 2-23 against K562 cells exposed to each derivative for 48 h, using analog 1 and imatinib mesilate as reference compounds. As shown in Table 1 , the IC 50 values of the new series ranged from 0.07 to 18 μM, and the AC 50 values ranged from 0.2 to 48 μM (except for compound 12, which was inactive at 50 μM). Out of the twenty-two derivatives, twelve (4-9, 11, 13, 15, 17, 18 and 20) exhibited good activity with IC 50 values lower than 1.0 μM.
Biological results

In vitro cytotoxic activity
The most active cytotoxic agent identified in this study was the 2-(3′,4′,5′-trimethoxybenzoyl)-3-methyl-5-(iodoacetylamino)-6-methoxybenzo[b]furan derivative 6, which showed an IC 50 1.8-and 3.1-fold lower than those of the reference derivatives 1 and imatinib, respectively. As an apoptotic agent, 6 was 1.8-and 2.7-times more active than 1 and imatinib, respectively. Compound 6 differed from 1 in the position of the iodoacetamido group and from compound 5, which had the iodoacetamido group in the same position as 6, in having a methyl substituent at position 3. It should be noted that, simply moving the iodoacetamido group, resulted in a 3.3-fold loss in antiproliferative activity, comparing the IC 50 obtained with 5 versus that obtained with 1.
For the 3-iodoacetamido benzo[b]furan derivatives 1-3, a comparison of substituent effect revealed that the cytotoxic activity was dependent on the methoxy substitution and on its location on the benzene portion of the benzo[b]furan moiety, with the most favorable position being C-6 (reference compound 1). The IC 50 obtained with 1 exceeded that obtained with the C-5 or C-7 methoxy counterparts 2 and 3 by more than one and two-orders of magnitude, respectively. A 7.5-fold reduction of activity was also observed following removal of the C-6 methoxy group of 1, to furnish derivative 4.
The IC 50 and AC 50 values obtained showed that the position of iodoacetylamino group on the benzo[b]furan system greatly affected antiproliferative activity, with the C-7 iodoacetylamino derivative 12 being inactive (IC 50 > 50 μM), while the C-3, C-4, C-5 and C-6 iodoacetamido derivatives 4, 8, 9 and 11, respectively, had comparable activity, with IC 50 values ranging from 0.6 to 0.9 μM. These compounds all differed from 1, in addition, by the absence of a methoxy substituent on the benzo[b]furan moiety. The activity of the 5-iodoacetamido derivative 9 was 30-fold reduced by the introduction of a methyl group at the C-3 position of benzo [b] furan nucleus (compound 10). However, this methyl substituent was also present, along with the 6-methoxy group, in the most active agent in the series, compound 6, while only the 6-methoxy yielded the less active compound 5.
Comparing derivatives 5 and 9 with their 3-methyl congeners 6 and 10, respectively, the introduction of a methyl at the C-3 position of compound 5 increased antiproliferative and apoptotic activity 6-and 8-fold, while an opposite effect was observed for compound 9, in which the C-3 methyl substitution produce a 30-and 10-fold reduction in cell growth inhibition and apoptotic potency, respectively.
Comparing the C-3 iodoacetamido derivatives without substituents on the benzene portion of benzoheterocyclic system (4, 13, 14 and 16), activity increased with indole (13) Returning to the benzo[b]thiophene derivatives, for compound 16, the least active in the group, simply moving the iodoacetylamino group from the C-3 to the C-5 position, to furnish derivative 17, led to a 22.5-and 6.7-fold increase in the cell growth inhibition and apoptotic activities. In addition, compound 18, bearing a methoxy substituent at the C-7 position, had activity similar to that of both 17 and 19, but this activity was 2-fold lower than that of the corresponding benzo[b]furan analog 7. In the benzo[b]thiophene group, the most active compound was 20, with a methyl substituent at position 3 (about twice as active as compounds 18 and 19, with a methoxy at position 7 or a methyl at position 6, respectively).
In a comparison of the cytotoxic and apoptotic activities of compounds 4 and 23, we found that the replacement of the trimethoxybenzoyl with a benzoyl moiety (compounds 4 and 23, respectively) maintained the IC 50 and AC 50 values, indicating that the trimethoxybenzene moiety was not required for activity in this compound class. However, both a single methoxy in the 4′ position (22) and two methoxy groups at the 3′ and 4′ positions (21) led to small and large losses of activity, respectively, in comparison with compounds with either the trimethoxybenzene (4) or unsubstituted benzene (23).
Analysis of cell cycle effects and pSTAT5 expression
Once the antiproliferative activity was determined, we examined the influence of the most active compounds (showing an IC50 ≤ 1 μM) on the cell cycle ( Fig. 1 , Table 2 ) and on pSTAT5 expression (Fig. 2, Table 3 ) in K562 cells. Analysis of cell cycle effects was carried out by flow cytometry after staining cells with propidium iodide; pSTAT5 expression was determined by flow cytometry after staining cells with a fluorochromeconjugated anti-pSTAT5 monoclonal antibody. In Fig. 2 , the curves expressing the fluorescence of cells stained with a fluoresceinated anti-pSTAT5 after a 24 h exposure to each compound (thick lines) were compared to those expressing the fluorescence of untreated cells stained with an anti-pSTAT5 (dotted lines) and to those stained with an isotype monoclonal antibody (thin lines). Although somewhat different multiples of the IC 50 values shown in Table 1 were used in the studies presented in Figs. 1 and 2, ranging from 1.9 for compound 7 to 7.1 for compound 6, these concentrations were minimally cytotoxic at 24 h, as opposed to the 48 h used in the antiproliferative studies.
The most active antiproliferative molecule 6 (IC 50 = 0.07 μM; AC 50 = 0.25 μM) caused an increase in the percentage of cells in the G2M phase of cell cycle (Fig. 1d , Table 2 ), and morphological examination of treated cells showed most cells were blocked in metaphase (data not shown). These findings indicate that compound 6 acts in cells as an antimitotic agent. Moreover, compound 6 was moderately active in decreasing the expression of activated STAT5 (pSTAT5) (Fig. 2c , Table 3 ; 44% inhibition relative to the untreated cells). Of interest, the two isomeric derivatives 5 and 7 (IC 50 = 0.4 μM; AC 50 = 2 μM) caused a modest increase in the proportion of cells in S phase and were unable (7) or only modestly able (5; 29% inhibition) to modify the expression of pSTAT5. In contrast, the benzo[b]thiophene derivative 20 induced a block of cells in G1 and a complete disappearance of activated pSTAT5 ( Fig. 2m and Table 3 ). Compounds 9 (IC 50 = 0.6 μM; AC 50 = 2.9 μM) and 13 (IC 50 = 0.5 μM; AC 50 = 2.4 μM) induced modest decreases in pSTAT5 expression (19 and 30% inhibition, respectively) and also caused modest increases in the proportion of cells in S phase (Figs. 1g, i and 2f, h; Tables 2 and 3 ). Compounds 4, 15, 20 and 23 blocked cells in G1, and they were markedly active in modulating STAT5. Compound 19 showed effects on cell cycle and on pSTAT5 similar to those of 6. Compounds 8, 11 and 17 caused modest increases in the proportion of cells in the S phase and had only minimal effects on pSTAT5 levels, while compound 18 caused the greatest increase in cells in the G2M phase (Fig. 1l , Table 2 ) and modestly decreased pSTAT5 expression (Fig. 2k , Table 3 ; 36% inhibition).
Inhibition of tubulin polymerization and colchicine binding
To investigate whether STAT5 modulation was related to an interaction with tubulin, compounds 4, 15, 20 and 23, the most active of the series in modulating STAT5, were selected to determine their inhibitory effects on tubulin polymerization and on the binding of colchicine to tubulin (Table 4) 
Discussion
STAT5 activation is correlated with functional effects on cell cycle progression and resistance to apoptosis through increased expression of cyclin D1 and Bcl-xl, respectively [11, 12] and is essential for leukemic cell survival [13, 15] . Moreover, many studies have shown that the constitutive STAT5 activation induced by the BCR-ABL oncogene plays an important role in the pathogenesis of CML [11] [12] [13] , as shown by evidence that murine STAT5-null bone marrow cells were inefficient in generating and maintaining a CML-like disease [16] .
Previously, we described the cytotoxic activity in BCR-AbL expressing cells of a new class of substituted 2-(3′,4′,5′-trimethoxybenzoyl)benzo[b]furan derivatives. The 2-(3′,4′,5′-trimethoxybenzoyl)-3-iodoacetylamino-6-methoxybenzo[b]furan derivative 1 showed somewhat greater antiproliferative activity than imatinib and had the ability to decrease intracellular levels of pSTAT5 [45] . With the aim to discover more potent compounds for inhibition of the phosphorylation-activation of STAT5, we designed a new series of 2-aroyl benzoheterocyclic derivatives structurally related to compound 1 and examined them for their ability to decrease pSTAT5 levels in K562 cells. SAR analysis indicated that (i) the benzo[b]furan nucleus was not indispensable for STAT5 inhibitory activity, for it could be replaced by benzo [b] thiophene or N-methyl indole systems, (ii) the ortho relationship between the benzoyl and the iodoacetylamino moieties at the C-2 and C-3 positions, respectively, of the benzoheterocyclic nucleus was essential for the STAT5 activity, and (iii) replacing the 3′,4′,5′-trimethoxybenzoyl moiety at the 2-position of benzo[b]furan skeleton with a benzoyl group maintained STAT5 inhibitory activity.
Compound 6 was the most active of the series in terms of antiproliferative and apoptosis activity (IC 50 = 0.07 μM, AC 50 = 0.25 μM). Compared to imatinib mesilate (IC 50 = 0.22 μM, AC 50 = 0.68 μM) it was 3 times more active as antiproliferative agent and 2 times more potent as apoptotic agent. The apoptotic effect observed with compound 6 in K562 cells is of interest considering that the Bcr-Abl oncogene expressed in this cell line confers resistance toward apoptosis induced by different agents. Although this compound seemed to act primarily as an antimitotic agent by blocking cells in the G2M phase, it also reduced the intracellular pSTAT5 levels. Compounds 18 and 19 also induced an arrest of cells in the G2M phase and were able to reduce the expression of pSTAT5. In contrast compounds 5, 7, 8, 9, 11, 13 and 17 increased the proportion of cells in the S phase, but these agents had little or no ability to modulate STAT5. Compounds 1, 15 and 20 were the most active in modulating STAT5 (they caused a complete or potent inhibition of STAT5 phosphorylation), and they strongly inhibited tubulin polymerization. However, these compounds caused a substantial increase in the proportion of cells in the G1 phase but not in the G2M phase as usually observed with antitubulin agents. This could be caused by their ability to potently inhibit STAT5 activation, thus preventing the G1 to S phase transition. In fact, pSTAT5 modulates the expression of genes that are known to regulate growth and survival, such as cyclin D1, Bcl-xl, c-Myc, pim-1, and p21 [48, 49] . In addition, several of the genes modulated by pSTAT5 are known to be associated with lympho-proliferative disorders. This includes nucleobindin, which is associated with non-Hodgkin's lymphoma [50] and MIP-1α, which is associated with multiple myeloma [51] .
Compared to the reference compound 1, derivative 20 was slightly less cytotoxic, but it was able to decrease intracellular pSTAT5 levels more potently than 1 and at a markedly lower concentration (1 μM vs 7.5 μM). Except for the two benzo[b]furan derivatives 4 and 23 that had good activity in decreasing pSTAT5 expression, but did not show antitubulin activity, our data suggest that there is a correlation between antitubulin activity and inhibition of STAT5 phosphorylation. This is supported by other studies that show that antimitotic agents can modulate STAT5 activity. Previous observations have shown the presence of a relationship between STATs nuclear translocation and microtubules. Indeed, the prevention of microtubule and microfilament polymerization induced a partial inhibition of STAT5 nuclear translocation and STAT5 DNA binding activity [52] . Moreover, paclitaxel, a microtubule stabilizer, significantly decreased the nuclear translocation of STATs without affecting the cytosolic tyrosine phosphorylation of these transcription factors [53] . LopezPerez and Salazar have shown that stimulation of MCF7 cells with epidermal growth factor (EGF) promoted an increase in the phosphorylation of STAT5 at Tyr-694 [52] . In addition, EGF stimulated STAT5 nuclear translocation and an increase in STAT5 DNA binding activity. STAT5 phosphorylation at Tyr-694 was dependent on the integrity of the microtubule network, and it was independent of the integrity of the actin cytoskeleton. This demonstrated for the first time that microtubules play an important role in STAT5 activation. Recently, a new microtubule destabilizing agent able to reduce phosphorylation/ activation of a member of the STAT family member was described [54] . These observations are consistent with our data that show a correlation between tubulin polymerization inhibition and STAT5 phosphorylation/activation.
Conclusions
Among the inhibitors of STAT5 protein, our previous work led to the identification of compound 1 as a potent STAT5 inhibitor. This agent contains the 2-(3′,4′,5′-trimethoxybenzoyl)-3-iodoacetamido-6-methoxybenzo[b]furan ring system. This finding prompted us to study this compound class in more detail by the preparation of a series of 2-(3′,4′,5′-trimethoxybenzoyl) benzoheterocyclic derivatives characterized by the presence of benzo[b]furan, benzo[b]thiophene, indole and N-methylindole ring systems and to determine which analogs were able to target STAT5 and disrupt STAT5 signaling. For most of the synthesized molecules, the 3′,4′,5′-trimethoxybenzoyl substituent was maintained at the 2-position of the benzoheterocycle, and we examined the effect on biological activity by altering the positions of the iodoacetamido group and of methyl and methoxy moieties, moving these substituents from the C-3 to C-7 positions. The SAR study indicated that the presence of the methoxy group located at the C-6 position of the benzo[b]furan nucleus contributed to maximal activity, since the C-5 and C-7 methoxy analogs 2 and 3, respectively, were considerably less active than the C-6 methoxy counterpart 1. In the series of 5-iodoacetamido benzo[b]furan derivatives 5-7 and 10, the greatest antiproliferative activity occurred with the concomitant presence of a methyl and methoxy group at the C-3 and C-6 positions, respectively, the least when a single methyl group was inserted at the C-3 position, to yield compounds 6 and 10, respectively, while the C-6 and C-7 methoxy analogs 5 and 7 were equipotent. The most active compound identified in this study was the 2-(3′,4′, Four compounds of this series (4, 15, 20 and 23) with substantially greater antiproliferative activity than 1 had significant inhibitory activities on STAT5 activation. These compounds, like reference compound 1, blocked cells in G1.
As with reference compound 1, derivatives 15 and 20 were able both to decrease the pSTAT5 level and to inhibit the assembly of tubulin by interacting with tubulin at the colchicine site. For the two benzo[b]furan derivatives 4 and 23, which were less active in modulating STAT5 than 1, 15 and 20, it was possible to achieve a complete separation between these two effects, since compounds 4 and 23 had minimal antitubulin activity The ability of 2-benzoyl-3-iodoacetamidobenzo[b]furan derivative 23 to reduce markedly the expression of activated STAT5 demonstrated that the presence of the three methoxy groups on the 2-benzoyl moiety was not essential for anti-STAT5 activity.
We have no specific evidence that our compounds alkylate intracellular proteins, thereby interfering with STAT activation, and we feel this possibility is too speculative to discuss at this time. The mechanism by which the new molecules 4, 15, 20 and 23 modulates STAT5 expression remains to be elucidated and is currently under investigation.
6. Experimental section 6.1. Chemistry 6.1.1. Materials and methods-1 H NMR and 13 C NMR spectra were determined in CDCl 3 or d 6 -DMSO solutions and recorded with a Varian VXR-200 spectrometer or a Varian Mercury Plus 400 spectrometer. Chemical shifts (δ) are given in parts per million (ppm) downfield and J values are given in hertz. Positive-ion electrospray ionization (ESI) mass spectra were recorded on a double-focusing ESI Micromass ZMD 2000 mass spectrometer. Melting points (mp) were determined on a Buchi-Tottoli apparatus and are uncorrected. Elemental analyses were conducted by the Microanalytical Laboratory of the Chemistry Department of the University of Ferrara and were performed on a Yanagimoto MT-5 CHN recorder analyzer. All tested compounds yielded data consistent with a purity of at least 95% as compared with the theoretical values. Reaction courses and product mixtures were routinely monitored by TLC on silica gel (precoated F 254 Merck plates) and visualized with aqueous KMnO 4 . Flash chromatography was performed using 230-400 mesh silica gel and the solvent system indicated in the procedure. All commercially available compounds were used without further purification. Organic solutions were dried over anhydrous Na 2 SO 4 . Petroleum ether refers to the fraction boiling at 40-60 °C.
General procedure A for the preparation of compounds 38-51-To
a solution of aminobenzoheterocyclic derivative 24-37 (1 mmol) and pyridine (3 mmol, 0.24 mL) in dry CH 2 Cl 2 (5 mL), bromoacetyl bromide (0.25 mL, 3 mmol) was added at 0 °C. After 1 h at the same temperature, the reaction mixture was diluted with CH 2 Cl 2 (5 mL), washed with water (5 mL), dried over Na 2 SO 4 and concentrated in vacuo. The crude residue was purified by flash chromatography on silica gel.
2-Bromo-N-(6-methoxy-2-(3,4,5-trimethoxybenzoyl)benzo-furan-5-yl)acetamide (38):
Following general procedure A, the crude residue purified by flash chromatography using ethyl acetate: petroleum ether 1:1 (v:v) as eluent furnished 38 as a white solid. Yield: 83%; mp 185-187 °C. 1 
2-Bromo-N-(6-methoxy-3-methyl-2-(3,4,5-trimethoxybenzoyl)benzofuran-5-yl)acetamide (39):
Following general procedure A, the crude residue purified by flash chromatography using ethyl acetate: petroleum ether 1:1 (v:v) as eluent furnished 39 as a yellow solid. Yield: 81%; mp 128-130 °C. 1 -N-(2-(3,4,5-trimethoxybenzoyl)benzofuran-4-yl) 6.1.2.9. 2-Bromo-N-(2-(3,4,5-trimethoxybenzoyl)-1H-indol-3-yl) 1.2.10. 2-Bromo-N-(1-methyl-2-(3,4,5-trimethoxybenzoyl)-1H-indol-3-yl) -N-(7-methoxy-1-methyl-2-(3,4,5-trimethoxybenzoyl)-1H-indol-3 
2-Bromo
2-Bromo-N-(2-(3,4-dimethoxybenzoyl)benzofuran-3-yl) acetamide (49):
Following general procedure A, the crude residue purified by flash chromatography using ethyl acetate: petroleum 
General procedure B for the synthesis of compounds 5-15 and 21-23-
A mixture of bromoacetamido derivatives 38-51 (1 mmol) and NaI (1.5 g, 10 mmol) in N,Ndimethylacetamide (5 mL) was stirred at ambient temperature for 18 h. N,N-dimethylacetamide was evaporated under reduced pressure, followed by addition of CH 2 Cl 2 (15 mL) and a solution of Na 2 S 2 O 3 (10%, 5 mL). The organic layer was washed with water (5 mL) and brine (5 mL) and dried over Na 2 SO 4 . After evaporation of the solvent, the residue was purified by flash chromatography on silica gel. 1.3.1. 2-Iodo-N-(6-methoxy-2-(3,4,5-trimethoxybenzoyl) 92 (s, 2H), 3.94 (s, 6H), 3.96 (s, 3H), 4.03 (s,  3H), 7.13 (s, 1H), 7.27 (s, 2H), 7.47 (s, 1H), 8.38 (bs, 1H), 8.68 (bs, 1H) . 13 1.3.2. 2-Iodo-N-(6-methoxy-3-methyl-2-(3,4,5-trimethoxybenzoyl) benzofuran-5-yl)acetamide (6): Following general procedure B, the crude residue purified by flash chromatography using ethyl acetate: petroleum ether 1:1 (v:v) as eluent furnished 6 as a yellow solid. Yield: 81%; mp 172-174 °C. 1 79 (s, 3H), 3.86 (s, 2H), 3.89 (s, 6H) 1.3.6. 2-Iodo-N-(3-methyl-2-(3,4,5-trimethoxybenzoyl) 6.1.3.10. 2-Iodo-N-(1-methyl-2-(3,4,5-trimethoxybenzoyl)-1H-indol-3-yl) Iodo-N-(7-methoxy-1-methyl-2-(3,4,5-trimethoxybenzoyl)-1H-indol-3 
6.
Biological assays. Materials and methods
6.2.1. Cell lines and culture-The K562 human myeloid cell line was used in this study. K562 express the anti-apoptotic oncogene BCR-ABL and high levels of phosphorylated STAT5. Cell lines were grown in RPMI 1640 (Gibco Grand Island, NY, USA) containing 10% FCS (Gibco), 100 U/ml penicillin (Gibco), 100 μg/ml streptomycin (Gibco), and 2 μM L-glutamine (Sigma Chemical Co., St. Louis, MO) in a 5% CO 2 atmosphere at 37 °C.
6.2.2.
Cell growth inhibitory activity-Cytotoxicity was evaluated by the trypan blue dye exclusion test. To determine the growth inhibitory activity of the drugs tested, 2 × 10 5 cells were plated into 25 mm wells (Costar, Cambridge, UK) in 1 mL of complete medium and treated with different concentrations of each drug. After a 48 h incubation, the number of viable cells was determined and expressed as percent of control proliferation.
6.2.3.
Apoptosis evaluation-Drug induced apoptosis and necrosis was determined morphologically after labeling the cells with acridine orange and ethidium bromide and by the annexin V detection test. In the morphological test, cells (2 × 10 5 ) were centrifuged (300× g) and the pellet was resuspended in 25 μL of the dye mixture. Ten microliters of the mixture was examined under oil immersion with a 100× objective using a fluorescence microscope. Live cells were determined by the uptake of acridine orange (green fluorescence) and exclusion of ethidium bromide (red fluorescence) stain. Live and dead apoptotic cells were identified by perinuclear condensation of chromatin stained by acridine orange (100 μg/mL) or ethidium bromide (100 μg/mL), and by the formation of apoptotic bodies. The percentage of apoptotic cells was determined after counting at least 300 cells. 
6.2.4.
Flow cytometry analysis of cell cycle and apoptosis-Cells were washed once in ice-cold PBS and resuspended at 1 × 10 6 per mL in a hypotonic fluorochrome solution containing propidium iodide (Sigma) 50 μg/mL in 0.1% sodium citrate plus 0.03% (v/v) nonidet P-40 (Sigma). After a 30 min incubation, the fluorescence of each sample was analyzed as single-parameter frequency histograms using a FACScan flow cytometer (Becton-Dickinson, San Jose, CA). The distribution of cells in the cell cycle was determined using the ModFit LT program (Verity Software House, Inc.). Apoptosis was determined by evaluating the percentage of hypodiploid nuclei accumulated in the sub-G 1 peak after labeling with propidium iodide. 6.2.6. Effects on tubulin polymerization and on colchicine binding to tubulinTo evaluate the effect of the compounds on tubulin assembly in vitro [55] , varying concentrations of compounds were pre-incubated with 10 μM bovine brain tubulin in glutamate buffer at 30 °C and then cooled to 0 °C. After addition of 0.4 μM GTP (final concentration), the mixtures were transferred to 0 °C cuvettes in a recording spectrophotometer and warmed to 30 °C. Tubulin assembly was followed turbidimetrically at 350 nm. The IC 50 was defined as the compound concentration that inhibited the extent of assembly by 50% after a 20 min incubation. The ability of the test compounds to inhibit colchicine binding to tubulin was measured as described [56] , except that the reaction mixtures contained 1 μM tubulin, 5 μM [ 3 H]colchicine and 5 μM test compound.
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